Ben Challis is VP and Head of Translational Science & Experimental Medicine in Early CVRM at AstraZeneca, a role in which he oversees the target validation, biomarker and precision medicine strategies for drug projects in the CVRM portfolio.

Ben completed his undergraduate training in Biochemistry & Chemistry at the University of Western Ontario. He completed his PhD at Cambridge University where he studied the genetics human obesity and insulin resistance. Ben obtained his MD from Cambridge University and completed specialist medical training in Internal Medicine & Endocrinology and Diabetes.

He is currently an Honorary Consultant in Endocrinology at Addenbrooke’s Hospital in Cambridge, and Director of Studies for Clinical Medicine at St Edmund’s college. His current research interests include metabolic disease & genetics and inherited tumour syndromes.